Group 1 - Huangshan Capsule's stock price has increased for seven consecutive days, with a cumulative rise of 5.98%, but experienced a decline of 2.59% on February 12 [1] - The stock price fluctuated significantly over the past seven trading days, with a closing price of 8.37 yuan on February 6, peaking at 8.53 yuan on February 11, and dropping to 8.29 yuan on February 12, resulting in a price range fluctuation of 2.99% [2] - The main business of Huangshan Capsule includes gelatin hollow capsules and enteric-coated gelatin hollow capsules, indicating a stable revenue structure [1] Group 2 - Institutional interest in Huangshan Capsule is relatively low, with a fund holding ratio of only 0.03% and a low ranking in industry research frequency, with ratings being neutral [3] - The earnings forecast for 2024 indicates an expected earnings per share of 0.16 yuan, with a projected net profit decline of 24.07%, suggesting limited improvement in fundamentals [3]

Group 1 - Haitai Xinguang, based in Qingdao, specializes in the research, production, and sales of medical endoscope instruments and optical products, being a leading enterprise in the domestic medical endoscope optical field [1][30] - The company has established long-term collaborations with international medical giants such as Karl Storz and Olympus, and its high-definition optical imaging technology supports navigation equipment for neurosurgery [1][30] - By 2026, the market demand for its high-end optical components is expected to further release due to the recovery of the medical device sector and the advancement of brain-computer interface medical applications [1][30] Group 2 - Huqiang Technology, registered in Yichang, focuses on special protective equipment, pharmaceutical packaging, and medical devices, with a strong advantage in public health emergency material supply [2][31] - Its medical protective equipment is applicable in sterile operating environments for brain-computer interface implantation surgeries, enhancing product competitiveness in the medical device sector [2][31] Group 3 - Zhengde Medical, headquartered in Shaoxing, is a leading enterprise in the medical dressing industry, with a product matrix covering medical dressings, infection control, and rehabilitation care [3][32] - The company's surgical infection control products meet the sterile operation requirements for brain-computer interface implantation surgeries, and its rehabilitation products cater to post-operative patient management needs [3][32] - By 2026, the surgical infection control consumables business is expected to see market growth as brain-computer interface medical applications accelerate [3][32] Group 4 - Linuo Pharmaceutical Packaging, based in Jinan, specializes in the research, production, and sales of pharmaceutical packaging materials, including sterile medical device packaging suitable for brain-computer interface components [4][33] - The company is gradually expanding into the high-end medical device packaging market, seizing opportunities in the brain-computer interface industry [4][33] Group 5 - Rendu Biotech, located in Shanghai, focuses on RNA molecular diagnostic technology, with applications in infection detection post-brain-computer interface implantation surgeries [5][34] - The company’s post-operative infection detection reagents are expected to see new demand growth by 2026 as brain-computer interface clinical surgeries are promoted [5][34] Group 6 - Huangshan Capsule, based in Anhui, specializes in the research and production of pharmaceutical hollow capsules, gradually expanding into medical device auxiliary materials [6][36] - The company’s medical capsule carriers can adapt to the encapsulation needs of sustained-release bioelectrodes in brain-computer interface devices [6][36] Group 7 - ST Kelly, headquartered in Suzhou, focuses on medical device research and production, particularly in ultrasound equipment and rehabilitation devices [7][37] - The company’s ultrasound diagnostic equipment can be used for pre-operative brain tissue imaging assessments in brain-computer interface surgeries [7][37] Group 8 - Aotai Biotech, based in Hangzhou, specializes in rapid diagnostic reagents, with its rapid infection detection reagents applicable in brain-computer interface clinical settings [8][38] - The company is developing rapid detection products for post-operative neurological function assessment related to brain-computer interfaces [8][38] Group 9 - Dongfang Ocean, located in Yantai, focuses on marine biological medical materials, with collagen materials applicable as coatings for brain-computer interface electrodes [9][39] - The company is increasing its R&D investment in the medical device sector, particularly in the integration of biological medical materials with brain-computer interface devices by 2026 [9][39] Group 10 - Shuoshi Biotech, based in Taizhou, specializes in nucleic acid detection technology, with products applicable for precise diagnosis of post-operative brain infections in brain-computer interface surgeries [10][40] - The company is exploring detection technologies related to neurotransmitters in brain-computer interfaces, aiming for breakthroughs in neurological disease diagnostics [10][40] Group 11 - Guofa Co., located in Beihai, focuses on pharmaceutical manufacturing and medical device sales, with a distribution network covering Guangxi and surrounding areas [11][41] - The company plans to increase its agency layout for high-end medical devices related to brain-computer interfaces by 2026 [11][41] Group 12 - Nanwei Co., based in Nantong, specializes in medical dressings and hygiene products, with its adhesive dressings suitable for post-operative care in brain-computer interface surgeries [12][42] - The company is enhancing its R&D on functional medical dressings, launching products tailored for long-term post-operative care in brain-computer interfaces [12][42] Group 13 - Mingde Biotech, located in Wuhan, is a leading enterprise in the field of rapid diagnostic reagents, with products applicable for monitoring vital signs during brain-computer interface surgeries [13][43] - The company is developing rapid assessment devices for post-operative neurological function related to brain-computer interfaces [13][43] Group 14 - Hualan Co., based in Wuxi, specializes in medical rubber products, with its rubber sealing components applicable in fluid control systems for brain-computer interface devices [14][44] - The company is collaborating with research institutions to develop rubber insulation components for brain-computer interface electrodes [14][44] Group 15 - Yuyue Medical, headquartered in Danyang, is a leading enterprise in home medical devices, with products applicable in brain-computer interface surgeries [15][45] - The company is increasing its R&D on medical-grade rehabilitation robots, aiming to integrate brain-computer interface technology with rehabilitation devices [15][45] Group 16 - Shengxiang Biotech, located in Changsha, focuses on nucleic acid detection technology, with products applicable for rapid diagnosis of central nervous system infections post-brain-computer interface surgeries [16][46] - The company is exploring gene detection technologies related to neurological genetic diseases, expanding the application boundaries of molecular diagnostics [16][46] Group 17 - Jiga Development, based in Jinan, focuses on high-end medical device incubation and industrialization, particularly in brain-computer interface-related medical device enterprises [17][47] - The company is responsible for industrial park construction and resource integration for brain-computer interface medical device companies [17][47] Group 18 - Anxu Biotech, located in Hangzhou, specializes in rapid diagnostic reagents, with products applicable for instant infection screening during brain-computer interface surgeries [18][48] - The company is developing rapid detection products for neurotransmitters related to brain-computer interfaces, aiming for breakthroughs in neurological function assessment [18][48] Group 19 - Wantai Biotech, based in Beijing, is a comprehensive enterprise in biopharmaceuticals and medical devices, with products applicable for biochemical index detection post-brain-computer interface surgeries [19][49] - The company is exploring biopharmaceutical development related to brain-computer interfaces, seeking new growth points in nerve repair [19][49] Group 20 - Jiuan Medical, located in Tianjin, focuses on home health devices, with products applicable for synchronized monitoring of brain signals and vital signs in brain-computer interface scenarios [20][50] - The company is increasing its R&D investment in brain-computer interface wearable devices, aiming to create an intelligent medical ecosystem [20][50] Group 21 - Jidan Biotech, based in Nanjing, specializes in POCT reagents and instruments, with products applicable for cardiovascular function assessment in brain-computer interface surgeries [21][51] - The company is developing rapid detection products for post-operative cerebrovascular diseases related to brain-computer interfaces [21][51] Group 22 - Wanfeng Biotech, located in Guangzhou, is a leading enterprise in the POCT field, with products applicable for instant infection screening during brain-computer interface surgeries [22][52] - The company is developing neurobiomarker detection reagents to assess post-operative neurological function recovery, providing comprehensive support for brain-computer interface surgeries [22][52] Group 23 - Haier Biotech, based in Qingdao, specializes in low-temperature storage devices for biological materials, with applications in brain-computer interface-related biological sample preservation [23][53] - The company is increasing its R&D on high-end medical storage devices tailored for brain-computer interface biological materials by 2026 [23][53] Group 24 - Haooubo, located in Suzhou, focuses on immune diagnostic reagents and instruments, with products applicable for immune function assessment in brain-computer interface surgeries [24][54] - The company is developing detection reagents for immune rejection post-brain-computer interface implantation, providing technical support for surgical complications [24][54] Group 25 - Shandong Pharmaceutical Glass, based in Zibo, is a leading enterprise in pharmaceutical glass, with products applicable for insulation packaging of brain-computer interface electrodes [25][55] - The company is expanding into the high-end medical device glass materials market, targeting the brain-computer interface industry [25][55] Group 26 - Innotech, located in Langfang, specializes in infectious disease diagnostic reagents, with products applicable for pre-operative lung infection screening in brain-computer interface surgeries [26][56] - The company is developing rapid detection products for post-operative lung infections related to brain-computer interfaces, aiming for breakthroughs in post-operative complication detection [26][56] Group 27 - Jianer Kang, based in Changzhou, focuses on medical dressings and rehabilitation care products, with its antibacterial medical dressings applicable for post-operative care in brain-computer interface surgeries [27][59] - The company is increasing its R&D on functional medical dressings, launching products tailored for long-term post-operative care in brain-computer interfaces [27][59]

Group 1 - The article reports on the dividend distribution announcements from three A-share listed companies: Heshun Petroleum, Southwest Securities, and Sanyuan Bio, with specific payout details provided [1] - Heshun Petroleum will distribute a dividend of 1.00 yuan per 10 shares (after tax 0.90 yuan) [1] - Southwest Securities will distribute a dividend of 0.10 yuan per 10 shares (after tax 0.09 yuan) [1] - Sanyuan Bio will distribute a dividend of 5.00 yuan per 10 shares (after tax 4.50 yuan) [1] Group 2 - The article lists several companies with their respective dividend record dates, including Guangzhou Restaurant, Fujian Expressway, New Media Co., Runhe Software, Huangshan Capsule, Province Advertising Group, and Suihengyun A [1] - Guangzhou Restaurant will have a record date for a dividend of 1.00 yuan per 10 shares (after tax 0.90 yuan) [1] - Fujian Expressway will have a record date for a dividend of 0.50 yuan per 10 shares (after tax 0.45 yuan) [1] - New Media Co. will have a record date for a dividend of 11.00 yuan per 10 shares (after tax 9.90 yuan) [1] - Runhe Software will have a record date for a dividend of 0.70 yuan per 10 shares (after tax 0.63 yuan) [1] - Huangshan Capsule will have a record date for a dividend of 0.33 yuan per 10 shares (after tax 0.297 yuan) [1] - Province Advertising Group will have a record date for a dividend of 0.11 yuan per 10 shares (after tax 0.099 yuan) [1] - Suihengyun A will have a record date for a dividend of 0.60 yuan per 10 shares (after tax 0.54 yuan) [1]

Core Viewpoint - The company, Anhui Huangshan Capsule Co., Ltd., has approved a profit distribution plan during its first extraordinary shareholders' meeting of 2025, which includes a cash dividend distribution to shareholders based on the current total share capital. Group 1: Profit Distribution Plan - The company will distribute a cash dividend of RMB 0.33 per 10 shares (including tax), totaling RMB 9,870,239.61 (including tax) based on the existing total share capital of 299,098,170 shares [2][3] - The distribution plan remains unchanged unless there is a change in the total share capital before the implementation [2] - The distribution plan is consistent with the one approved during the shareholders' meeting [2] Group 2: Dividend Payment Dates - The record date for the dividend distribution is set for December 30, 2025, and the ex-dividend date is December 31, 2025 [3] Group 3: Dividend Recipients - The recipients of the dividend will be all shareholders registered with the China Securities Depository and Clearing Corporation Limited, Shenzhen Branch, as of the close of trading on December 30, 2025 [4] Group 4: Distribution Method - The cash dividends will be directly credited to the shareholders' accounts through their securities custodians on December 31, 2025 [5] Group 5: Consultation Information - For inquiries, shareholders can contact the company's securities department at the provided address and phone numbers [6]

Group 1 - The company Huangshan Capsule (002817.SZ) announced a cash dividend distribution of 0.330000 RMB per 10 shares for all shareholders, based on a total share capital of 299,098,170 shares [1] - For specific investors, including those holding shares through the Shenzhen-Hong Kong Stock Connect and certain foreign institutions, the cash dividend will be 0.297000 RMB per 10 shares after tax [1] - The record date for the dividend distribution is set for December 30, 2025, and the ex-dividend date is December 31, 2025 [2]

Core Viewpoint - Huangshan Capsule announced a cash dividend distribution plan for the first three quarters of 2025, indicating a commitment to returning value to shareholders [1] Group 1: Dividend Announcement - The company will distribute a cash dividend of 0.33 RMB per 10 shares to all shareholders, which includes tax [1] - The record date for the dividend distribution is set for December 30, 2025, and the ex-dividend date is December 31, 2025 [1] - Cash dividends will be directly credited to shareholders' accounts through their securities companies on December 31, 2025 [1]

证券代码：002817 证券简称：黄山胶囊 公告编号：2025-041 安徽黄山胶囊股份有限公司 2025 年前三季度分红派息实施公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或者重大遗漏。 一、股东会审议通过利润分配方案的情况 本公司 2025 年前三季度权益分派方案为：以公司现有总股本 299,098,170 股为基数，向全体股东每 10 股派 0.330000 元人民币现金（含税；扣税后，通过 深股通持有股份的香港市场投资者、境外机构（含 QFII、RQFII）以及持有首发 前限售股的个人和证券投资基金每 10 股派 0.297000 元；持有首发后限售股、股 权激励限售股及无限售流通股的个人股息红利税实行差别化税率征收，本公司暂 不扣缴个人所得税，待个人转让股票时，根据其持股期限计算应纳税额【注】； 持有首发后限售股、股权激励限售股及无限售流通股的证券投资基金所涉红利税， 对香港投资者持有基金份额部分按 10%征收，对内地投资者持有基金份额部分实 行差别化税率征收），【注：根据先进先出的原则，以投资者证券账户为单位计 算持股期限，持股 1 个月（含 1 个月 ...

Group 1 - The company Huangshan Capsule (002817) announced the appointment of three new deputy general managers: Mr. Chu Zhenhua, Mr. Fan Jian, and Mr. Zhang Wenzheng [1]

Group 1 - The core point of the article is the appointment of Dong Xue as the manager of the audit department at Huangshan Capsule (002817) [1]

Group 1 - The core point of the article is that Huangshan Capsule (002817) announced the appointment of Mr. Liu Qingke as the Chief Financial Officer [1] Group 2 - The announcement was made on the evening of December 18 [1]